Search the Newsreel

Indivior Leadership to Host Aug. 4 Webcast After Q2 Results

Indivior (INDV) Q1 2026 earnings summary

Indivior (INDV) reported strong Q1 2026 earnings, with net revenue increasing 19% year-over-year to $317 million, largely due to a 32–33% rise in SUBLOCADE sales. Adjusted EBITDA saw a significant jump of 112% to $164 million, and net income almost doubled to $89 million. …

Indivior stock trades steady as opioid treatment specialist rebuilds after 2024 setback

Indivior PLC is rebuilding investor confidence after a challenging 2024 marked by significant litigation costs that led to a net loss of $140 million, despite stable revenue and improved adjusted operating profit. The company is focusing on strengthening its balance sheet through debt reduction …

Indivior stock holds a recovery path as opioid treatment demand supports revenue

Indivior PLC's stock is showing signs of recovery, driven by strong demand for its opioid use disorder treatments and its ability to manage past legal settlements. The company's revenue growth, profitability metrics, and market capitalization are key indicators investors use to evaluate its balance …

Indivior stock trades steadily as recent earnings and guidance frame addiction-treatment strategy

Indivior stock is trading steadily despite ongoing scrutiny, reflecting strong earnings, improved margins, and reduced legal provisions. The company, focused on addiction treatment, reported annual revenue above $1 billion in fiscal 2025 and improved operating cash flow. Investors are closely watching prescription volumes for …

Indivior stock trades steady as revenue grows and opioid treatment portfolio expands

Indivior PLC, a specialty pharmaceutical company focused on opioid use disorder and addiction treatments, shows steady stock performance driven by growing revenues and resilient margins. The company's financial health is supported by its buprenorphine-based products, diversification into extended-release injectable formulations, and disciplined cost management, …

Indivior stock trades steady as opioid treatment specialist focuses on growth after recent earnings

Indivior's stock performance is influenced by the balance between its growing opioid use disorder treatment sales and ongoing legal settlement costs. The company's recent earnings show strong revenue growth driven by its flagship opioid use disorder therapies, with profitability metrics indicating underlying operational strength …

Indivior stock holds steady as addiction-treatment strategy stays in focus

Indivior stock reflects the company's focus on addiction therapies, particularly opioid use disorder, positioning it within long-term healthcare trends. The company's strategy involves expanding treatment options, operating within a heavily regulated environment, and facing competition in a specialized niche. Its long-term approach includes R&D …

How Investors Are Reacting To Indivior (INDV) Upgraded 2026 Outlook And $175 Million Buyback Plan

INDV Stock: What Sublocade Growth Signals for 2026

Indivior Q1 Earnings Call Highlights

Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics

Indivior: Still Attractive After FY25 Earnings Beat (NASDAQ:INDV)